Abstract. Secretin receptor (SCTR), the G-protein coupled receptor (GPCR) for secretin, has been observed to be upregulated in a few tumor types while downregulated in others, promoting or suppressing the proliferation of tumor cells, respectively. However, little is known about the molecular regulatory mechanism of dysregulation in cancer. In the present study, an analysis of the biological pathways affected by methylation in breast cancer using the methylome databases revealed that GPCRs played a major part in the affected pathway. SCTR, one of the dysregulated GPCRs, showed hypermethylation (P<0.01) and downregulation (P<0.05) in breast cancer tissues. Pathway analysis after the downregulation of SCTR by siRNA in MCF-10A cells identified the G2/M stage checkpoint as the top-scored pathway. Cell cycle-related genes were all upregulated or downregulated suppressing cell proliferation. However, the overexpression of SCTR in MCF-7 cells led to a 35% increase of the cell proliferation index and 2.1-fold increase of cellular migration. Our findings indicate that SCTR suppresses the proliferation of normal breast cells, while the gene stimulates the proliferation and migration of cancer cells being downregulated by promoter methylation.
Introduction
G-protein coupled receptors (GPCRs) are membrane-spanning protein receptors characterized by a variable number of ligands that include endogenous neurotransmitters and hormones, but also exogenous natural and artificial compounds (1, 2) . More than 600 GPCRs have been identified in humans, and their activation results in diverse physiological changes. Upon binding to receptors, agonists trigger the activation of signaling pathways; whereas, antagonists impede the agonistmediated activation of the receptors. Inverse agonists, besides interfering with agonists as do antagonists, suppress the constitutive activity of receptors (3, 4) .
In many cases, the dysregulation of GPCRs has been linked to the development of cancer, and hence, these proteins are of great interest to academia and the pharmaceutical industry. The overexpression of GPCRs has been revealed in a variety of cancer types. For example, an elevated GPER protein expression was revealed in embryonal carcinomas as well as in testicular stromal neoplasms (5, 6) . CXCR4, one of the best established chemokine receptors, is highly expressed in breast cancer cells (7) . The HER2/Neu oncogene, which occurs in ~30% of breast cancers, limits the degradation of CXCR4, leading to its increased expression. In certain malignancies, some GPCRs and G proteins may play tumorsuppressive roles, and mutations may reflect the inactivation of the respective genes. For example, inactivating mutations in the melanocortin 1 receptor (MC1R), which is important for pigment production, increase the risk of melanoma development (8) . Additionally, SIP2 receptor signaling through Gα 13 in diffuse large B cell lymphoma (DLBCL) may exert tumorsuppressive functions (9) .
Secretin receptor (SCTR) is a GPCR to which secretin binds, and it has long been known to mediate the effect of the gastrointestinal hormone on digestion and water homeostasis (10, 11) . In physiological conditions, SCTR is highly expressed in secretin target organs (e.g., pancreas, kidney and small intestine), and it is expressed in the distal lung regions and liver, with trace levels in the brain, heart and ovaries (12 (13) (14) (15) . In contrast, SCTR has been found to be downregulated in colorectal cancer (16) and prostate cancer (17) . Many tumor-related genes are known to be regulated by epigenetic mechanisms, including DNA methylation. Genes that are downregulated and hypermethylated in breast cancer include BRCA1, PTEN and RASSF1 (18) (19) (20) . Regarding SCTR, its CpG island methylation has not yet been extensively reported in cancer. Only a large chromosomal region at 2q14.2 that spans EN1, SCTR and INHBB is known to be silenced in colorectal cancer (16) .
In the present study, using an in silico approach, we found that SCTR was downregulated in all stages of breast cancer cell lines. After confirming the downregulation in cancer tissue, we tried to elucidate the epigenetic mechanism of the dysregulation by examining the promoter methylation. Furthermore, the gene was induced to be downregulated using siRNA, and a gene interaction network was constructed from the affected gene pool. Finally, the cell proliferation and migration activities of SCTR were monitored based on the information from the siRNA-knockdown experiment.
Materials and methods
In silico database analysis. The Infinium Methylation Chip data for a normal breast cell line, MCF-10A, and 10 cancer cell lines ranging from tumor stage I-Iv were obtained from the GEO database (http://www.ncbi.nlm.nih.gov/geo/). The adopted accession number for normal breast cell is GSM443815. In cancer cells, the data used in stage I is GSM443818, stage II is GSM443811, GSM443817, GSM443812, GSM443819 and GSM664892, stage III is GSM443813 and GSM443814 and stage Iv is GSM443816, GSM664906 and GSM443821. The Illumina Infinium Methylation Assay detects genome-wide methylation covering 27,578 CpG sites in 14,495 genes. Observations with adjusted P-values ≥0.05 were removed and thus excluded from further analysis. Following adjustment, the genes of the cancer cell lines were defined as differentially methylated if they displayed an increased or decreased methylation level of at least 2-fold compared to that of the normal cell line. The Student's t-test was used to detect differences in mean levels of methylation and the expression level between the normal and cancer tissues using SPSS for Windows, version 17.0 (SPSS Inc., Chicago, IL, USA). P-values <0.05 were considered statistically significant.
Cell culture and transfection. The breast cancer cell line MCF-7 and the normal breast cell line MCF-10A, were purchased from the American Type Culture Collection (ATCC; Manassas, vA, USA). MCF-10A was grown in MEBM (Lonza, Basel, Switzerland) supplemented with MEGM SingleQuots (Lonza) and cholera toxin (List Biological Laboratories, Inc., Campbell, CA, USA). MCF-7 was grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS). All cells were cultured on the surface of a 75-cm 2 culture flask. siRNA-based downregulation of SCTR was carried out by transiently transfecting the siRNA against SCTR into the MCF-10A cell cultures in a 60-mm culture dish. siRNA of the gene and a control siRNA were purchased from SigmaAldrich (St. Louis, MO, USA) and added to the culture media up to 200 nM in final concentration using a Lipofectamine RNAiMAX reagent (Invitrogen, Carlsbad, CA, USA). The cells were harvested 48 h after transfection for RNA isolation.
To establish stable cell lines expressing SCTR, 2 µg of SCTR-expressing vector (GeneCopoeia, Germantown, MA, USA) was transfected into 1x10 6 of MCF-7 cells in a 75-cm 2 culture flask using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. A vector without the gene was used as a control. Two days after transfection, neomycin (400 µg/ml) (Gibco-BRL, Carlsbad, CA, USA) was added to select stable transfectants. The expression of SCTR was monitored by reverse transcription-polymerase chain reaction (RT-PCR).
Study subjects. Twenty-one pairs of breast cancer (BrCa) specimens and their corresponding adjacent normal tissue specimens were obtained from patients who had undergone surgery between 2011 and 2012 at the National Cancer Center (NCC) in Korea. All patients provided written informed consent to donate removed tissue to the NCC, and samples were obtained according to protocols approved by the Research Ethics Board of the NCC. BrCa specimens were subjected to histological examination by an expert pathologist for independent confirmation of tumor grade.
Real-time RT-PCR.
Total RNA from ~100 mg of tissue was isolated using TRIzol reagent according to the manufacturer's protocol (Gibco-BRL) with a final suspension in 30 µl of distilled water. Total RNA from a 75-cm 2 culture flask was isolated using the RNeasy Plus Mini kit (Qiagen) with a final elution in 30 µl of distilled water. Reverse transcription was conducted using 1-5 µg of total RNA with a reverse transcription kit (Toyobo, Osaka, Japan). Gene expression was measured by real-time quantitative RT-PCR analysis using a Kapa SYBR FAST qPCR kit (Kapa Biosystems, Inc., Woburn, MA, USA) on an ABI 7300 instrument (Applied Biosystems, Foster City, CA, USA). One microliter of cDNA was used for PCR, which was performed in duplicate. The primers used for SCTR are forward, 5'-GATGTCACCTACTGCGATGC-3' and reverse, 5'-ACAAAAATGGCTGGAGAACC-3'. RNA quantity was normalized to GAPDH content, and gene expression was quantified according to the 2 -ΔCt method. Primer sequences for GAPDH are forward, 5'-CAGGAGGCATTGCTGATGAT-3' and reverse, 5'-GAAGGCTGGGGCTCATTT-3'.
Methylation-specific PCR. Chromosomal DNA from ~100 mg of tissue samples was isolated using a genomic DNA purification kit (Promega, Madison, WI, USA) according to the manufacturer's protocol with a 60-µl elution volume. Sodium bisulfite modification of genomic DNA and PCR were carried out as previously described (18) . Briefly, 0.1 mg of DNA was treated with sodium bisulfite, and then PCR was carried out using primers and a Kapa SYBR FAST qPCR kit (Kapa Biosystems). The primer sequences of methylated SCTR are forward, 5'-TTTGGAGTTTACGGATAGAAAGC-3' and reverse, 5'-CCGAAAATAAATATTATCAAACGTA-3'. Unmethylated SCTR are forward, 5'-TTTGGAGTTTATGG ATAGAAAGTGT-3' and reverse, 5'-TCCAAAAATAAAT ATTATCAAACATA-3'. A methylation index was calculated for each sample using the following formula:
] x 100%, where CTu and CTme are the cycle threshold obtained using the unmethylated and the methylated primer pair, respectively.
Expression microarrays and pathway analysis. An Illumina
HumanHT-12 v4 Expression BeadChip (Illumina, San Diego, CA, USA) analysis covering 31,000 human genes and containing 47,231 probes was performed by Macrogen (Seoul, Korea). Briefly, biotinylated cRNA was prepared from 550 ng of total RNA using the Illumina TotalPrep RNA amplification kit (Ambion, Austin, TX, USA). Fluorescent signals were obtained by scanning with iScan System, and data were extracted with Gene Expression Module 1.9.0 in GenomeStudio v2011.1 (Illumina). Data were processed by excluding genes with the detection P-values ≥0.05, and differentially expressed genes displaying at least a 2-fold difference between the control cells and the siRNA treated cells were obtained. The array data were uploaded to the Gene Expression Omnibus (GEO) database, and they can be accessed via their website (http:// www.ncbi.nlm.nih.gov/geo/; accession number GSE60750).
Functional categorization and pathway construction for the gene pool obtained from the affected genes by siRNA or overexpressed SCTR were performed using the Ingenuity Pathway Analysis (IPA) software tool (Ingenuity Systems, Redwood City, CA, USA) (16) . P-values for individual networks were obtained by comparing the likelihood of obtaining the same number of transcripts or greater in a random gene set as were actually present in the input file (i.e., the set of genes differentially methylated in normal and tumor tissue) using Fisher's exact test, based on the hypergeometric distribution. The highest confidence functional network was designated as the top network.
Cell proliferation and migration analysis. Cells cultured in a 60-mm dish at ~80% confluence were harvested using 0.05% Trypsin-EDTA (Gibco-BRL), washed with PBS, and then fixed in ice-cold 70% ethanol overnight. The cells were treated with 50 µg/ml RNaseA (Sigma-Aldrich) for 1 h and then stained with 50 µg/ml propidium iodide (Sigma-Aldrich) in the dark for 30 min at room temperature. Samples were analyzed using a FACSCanto II flow cytometer (Becton-Dickinson, Franklin Lakes, NJ, USA) reading with a 488-nm laser. The cell proliferation index was calculated using the following formula: Proliferation index = (S+G2+M)/(G0/G1+S+G2+M) x 100%, where each letter represents the number of cells at each stage.
For cell migration assay, cells were plated onto 8.0 µm Transwell Inserts (Corning Life Sciences, Tewksbury, MA, USA) and cultured following the supplier's protocol. The migrated cells were stained with crystal violet and counted under a microscope. The migration ratio was calculated by dividing the number of migrated cells by the number of cells seeded.
Results

Various GPCRs are aberrantly methylated in breast cancer.
To identify novel GPCRs that are deregulated by aberrant promoter methylation in breast cancer, a series of in silico analysis was performed on genome-wide methylation databases. The Illumina methylation assay data from a normal breast cell line and 10 breast cancer cell lines of stage I-Iv were extracted from the GEO database. After filtrating out statistically insignificant CpG sites (P>0.05), the β-values of remaining CpGs, indicative of the methylation level, were compared between the normal cell line and each cancer cell line. Screening of CpG sites fitting our criteria with 2-fold higher or lower methylation in cancer than in normal cells presented 808-1,517 CpGs which included 114 GPCRs. The GPCRs that showed the highest change of hypermethylation and hypomethylation were LPAR2 (33.3-fold) and GPR133 (-18.8-fold), GALR3 (19.9-fold) and GPR135 (-20.3-fold), QRFPR (20.9-fold) and CELSR1 (-21.3-fold), and GPR56 (16.7-fold) and BDKRB2 (18.1-fold) at stages I-Iv, respectively.
SCTR is hypermethylated and downregulated in breast cancer. Among the aberrantly methylated GPCRs, the ones that frequently appear throughout the four cancer stages were selected for further examination. Twenty-four GPCRs (e.g., GPR135, TAS1R2 and SCTR) hit more than three stages (Table I) . Three GPCRs, TAS1R2, F2RL2 and SCTR, whose methylation status is not yet known in any cancer tissue, were selected for further examination in breast cancer tissue. Twenty-one pairs of tumor and nearby normal tissue were examined by real-time methylation-specific PCR (MSP) and RT-PCR to monitor methylation and expression, respectively. The results indicated that only SCTR showed higher methylation levels (P<0.05) and downregulation (P<0.05) in cancer tissues than in normal tissues with a statistical significance (Fig. 1) . SCTR, therefore, was selected to further address its role in breast cancer.
SCTR regulates cell cycle-related genes.
To address the role of SCTR in breast cancer, knockdown was induced by transiently transfecting siRNA, which targeted the message in the MCF-10A cells, and then genome-wide expression change was monitored through microarray analysis. In total, 1,587 genes fitting our criteria of expression change >2-fold with 993 upregulated and 594 downregulated genes were submitted to the IPA. The results indicated the 'cellular movement, cancer, connective tissue disorders' as the top network and 'cell cycle: G2/M DNA damage checkpoint regulation' as the top pathway, implying its role in tumorigenesis ( Fig. 2 and Table II) . Notably, the majority of the cell cycle-related genes in the network were upregulated or downregulated in a way increasing cell proliferation after SCTR was downregulated by siRNA, suggesting SCTR has anti-proliferative activity in normal cells. In the network, three kinases, TNK2 (ACK1), DDR1 and CDCP1, all of which are known to be oncogenic proteins, were upregulated (21-23). Whereas, DICER1, TPM1 and RGS2, all of which are known to be related with tumor-suppressing activity, were downregulated in the network (24) (25) (26) . Therefore, it is expected that the genes would show upregulation or downregulation in cancer if they are oncogenic or tumor-suppressive, respectively. The in silico expression analysis based on the Oncomine database platform confirmed the upregulation of TNK2 (ACK1), DDR1, and CDCP1 and the downregulation of DICER1, TPM1 and RGS2 in the breast cancer cells (Fig. 3) .
To examine the cell cycle-related activity of SCTR, the MCF-10A normal breast cells wherein the SCTR was downregulated by siRNA were monitored for cell proliferation index by FACS analysis. The result indicated, unexpectedly, that no remarkable change of the cell proliferation index was observed (Fig. 4) . To determine whether the effect of SCTR on the cell cycle differs between normal and cancer cells, the gene was overexpressed in the MCF-7 cancer cells by stable transfection (Fig. 5A) , and the cells were monitored for cellcycle status (Fig. 5B) . The result indicated a 35% increase of the cell proliferation index with a 9% decrease of G1 phase cells but a 39% increase of S and G2/M phase cells. Next, the effect of SCTR on the migration of the cancer cells was examined for the SCTR-overexpressing MCF-7 cells, and the cells showed a 2.1-fold increase of migration compared to the MCF-7 cells (Fig. 5C ). These facts suggest that SCTR Table I . GPCRs displaying differential methylation at breast tumor stage I-Iv. stimulates cell migration as well as cell proliferation of the MCF-7 cancer cells by regulating cell cycle-related genes.
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Discussion
GPCRs modulate diverse cellular responses to the majority of neurotransmitters and hormones within the human body (27) . various GPCRs have been found to be overexpressed in primary and metastatic tumors (28, 29) . In breast cancer, specific GPCR systems are excessively activated in malignant breast cancer due to the overexpression of receptors, which contributes to the progression and spread of breast cancer (30, 31) . For example, GPR30, a seven membranespanning estrogen receptor, is linked to estrogen binding and heparin-bound epidermal growth factor release, and it induces the proliferation and migration of breast cancer cells through connective tissue growth factor (32, 33) . For these reasons, GPCRs have long been the most promising targets for developing therapeutic agents (34) . For instance, an adhesion GPCR, CD97, was targeted by lysophosphatidic acid in the MDA-MB-231 breast cancer cells (35) .
In the present study, many GPCRs showed aberrant methylation, with some being hypermethylated and others being hypomethylated in breast cancer. These differential methylation profiles of the GPCRs should direct their expression in such a way as to specifically contribute to carcinogenesis. In the case of SCTR, a high frequency of methylation at the gene's CpG island was revealed in colorectal cancer, although its relationship to expression has yet to be determined (36) . The roles of SCTR have been elucidated only in a few cancer types. When transfected into Y1 adrenocortical carcinoma cells, overexpressing SCTR stimulated cell proliferation via the PI3K/AKT signaling cascade (37).
Whether SCTR is an oncogene or a tumor suppressor is still controversial. Several studies support the idea that it is an oncogene, as high expression was observed in a few cancer types, such as pancreatic ductal adenocarcinoma and gastrinoma (13, 15) , whereas, other studies indicate the downregulation of the gene in colorectal cancer, cholangiocarcinoma and prostate cancer (14, 16, 17) . Notably, the differential regulation occurs in a tissue-specific manner, and this drove us to profile the expression in breast cancer.
In the present study, the authors suggested unique regulatory activities of SCTR in breast cells (i.e., tumor-suppressive activity in normal cells and proliferation-and migrationstimulating activity in cancer cells). Several experimental results support our hypothesis. First, the downregulation of SCTR by siRNA in normal breast MCF-10A cells, dysregulated oncogenes or tumor suppressors toward suppressing tumor development; oncogenes were upregulated, and tumor suppressors were downregulated by siRNA. Second, the overexpression of SCTR in MCF-7 breast cancer cells increased the proliferation rate of the cells, while little effect on normal cells was observed when the gene was downregulated. Third, the overexpression of SCTR in MCF-7 cancer cells increased cell migration. The so-called double-edge sword activity of tumor-related genes (i.e., upholding both oncogenic and tumor-suppressive activity) are known for genes involved in key signaling pathways, such as TGF-β1 and JNK. TGF-β1 is a potent growth inhibitor, with tumor-suppressing activity. Cancers are often refractile to this growth inhibition because of the downstream perturbation of the signaling pathway (38) . JNK has pro-or anti-apoptotic functions depending on the cell type, nature of the death stimulus, duration of its activation, and activity of other signaling pathways (39) . The molecular mechanism of SCTR for negative and positive regulation in terms of the cell proliferation that appeared in normal and cancer cells is to be elucidated in further studies.
The signaling pathway via GPCR is a highly complicated process. NF-κB, β-catenin and PI3Kγ are major signaling genes aberrantly regulated in cancer (40) . In the present study, IL-8 was upregulated after inhibiting SCTR, implying that SCTR is able to suppress IL-8 expression. IL-8 is reported to promote breast cancer by increasing cell invasion, angiogenesis, and metastases (41, 42) . The signaling pathway connecting SCTR and IL-8 should be elucidated in future studies. Genes known to interact with IL-8 in the network (Fig. 2) (e.g., DDR1 , TNFRSF12A and DICER1) could be informative. Taken together, it is speculated that SCTR acts as a tumor suppressor in normal breast tissue. However, the gene has a tendency to proliferate breast cancer cells although it is downregulated in cancer by promoter methylation.
